37 results on '"Pérez-Ceballos, Elena"'
Search Results
2. Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group
3. Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
4. Accuracy and prognostic impact of FDG PET / CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation‐Wide cohort study
5. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas
6. Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin
7. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial
8. Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings
9. Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: Influence of geographical factors and occupational exposure
10. MCL-113: IBRORS-MCL Study: A Spanish Retrospective and Observational Study of Relapsed/Refractory Mantle-Cell Lymphoma (MCL) Treated with Ibrutinib in Routine Clinical Practice
11. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkinʼs lymphoma patients at high risk of central nervous system disease in the rituximab era
12. Protein Z-dependent protease inhibitor W303X mutation in venous thrombosis
13. Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods
14. Prothrombin A19911G and G20210A polymorphisms' role in thrombosis
15. Nuevas estrategías en la preparación y almacenamiento de los concentrados de plaquetas / Elena Pérez Ceballos ; dirección, Mª Luisa Lozano Almela y José Rivero Pozo
16. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)
17. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma
18. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy
19. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy
20. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma
21. l-Asparaginase-Induced Antithrombin Type I Deficiency : Implications for Conformational Diseases
22. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas
23. Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study
24. Phase II trial of ofatumumab plus ESHAP (O- ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
25. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
26. Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: Influence of geographical factors and occupational exposure
27. Reactivación de la hepatitis B en un paciente HBsAg negativo/antiHBc positivo con linfoma B que recibió quimioterapia con rituximab
28. Comparison Between Lymphoglobuline- and Thymoglobuline-Based Immunosuppressive Therapy as First-Line Treatment for Patients with Aplastic Anemia.
29. “Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stem-Cell Transplantation as Therapy of Mantle Cell Lymphoma. Results of Manto 2000 study”.
30. Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication
31. Computed Tomography (CT) Predicts Response Duration in Patients with Chronic Lymphocytic Leukemia (CLL) in Complete Response (CR) by Conventional, NCI-Working Group, Criteria.
32. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis
33. l-Asparaginase-Induced Antithrombin Type I Deficiency
34. Salvage Treatment with Ofatumumab and ESHAP (O-ESHAP) for Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma After First-Line Chemotherapy: Interim Analysis of a Phase II Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)
35. SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment.
36. Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study.
37. [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.